Table 3.
Strategy | Pro | Con |
---|---|---|
DM screening among TB patients | Possible improvement of individual patient outcome | No expected population impact |
Better management of combined TB and DM | Possible improvement of individual patient outcome | No expected population impact |
A more effective TB vaccine | Massive impact, also beyond DM-associated TB | Not available yet |
Better DM management | Massive impact on all DM complications and mortality, especially related to cardiovascular disease | Challenging, especially in low-resource settings |
TB preventive therapy for people with DM and LTBI | Projected reduction of individual TB risk, with significant population impact in terms of TB control | No evidence from phase 3 trials yet |
Prevent diabetes incidence | Potentially massive impact on population health, CVD risk and saving substantial health care resources | Requires substantial shift in population diet and reductions in obesity. Limited evidence how to scale up to whole populations in LMIC |
DM, diabetes; LTBI, latent tuberculosis infection; CVD, cardiovascular disease.